Search Results

There are 122684 results for: content related to: Pseudoporphyria induced by imatinib mesylate

  1. Human hepatocyte assessment of imatinib drug–drug interactions – complexities in clinical translation

    British Journal of Clinical Pharmacology

    Volume 80, Issue 5, November 2015, Pages: 1097–1108, Jan H. Beumer, Venkateswaran C. Pillai, Robert A. Parise, Susan M. Christner, Brian F. Kiesel, Michelle A. Rudek and Raman Venkataramanan

    Version of Record online : 19 SEP 2015, DOI: 10.1111/bcp.12723

  2. You have free access to this content
    Effects of imatinib mesylate on the spontaneous activity generated by the guinea-pig prostate

    BJU International

    Volume 112, Issue 4, August 2013, Pages: E398–E405, Michelle Lam, Anupa Dey, Richard J. Lang and Betty Exintaris

    Version of Record online : 23 JUL 2013, DOI: 10.1111/j.1464-410X.2012.11660.x

  3. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 1138–1144, S. Prey, K. Ezzedine, A. Doussau, A.-S. Grandoulier, D. Barcat, E. Chatelus, E. Diot, C. Durant, E. Hachulla, J.-D. de Korwin-Krokowski, E. Kostrzewa, T. Quemeneur, C. Paul, T. Schaeverbeke, J. Seneschal, A. Solanilla, A. Sparsa, S. Bouchet, S. Lepreux, F.-X. Mahon, G. Chene and A. Taïeb

    Version of Record online : 5 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11186.x

  4. You have free access to this content
    Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates

    British Journal of Pharmacology

    Volume 165, Issue 8, April 2012, Pages: 2787–2798, AM Filppula, J Laitila, PJ Neuvonen and JT Backman

    Version of Record online : 23 MAR 2012, DOI: 10.1111/j.1476-5381.2011.01732.x

  5. You have free access to this content
    Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

    Arthritis & Rheumatism

    Volume 56, Issue 1, January 2007, Pages: 311–322, Jörg H. W. Distler, Astrid Jüngel, Lars C. Huber, Ursula Schulze-Horsel, Jochen Zwerina, Renate E. Gay, Beat A. Michel, Thomas Hauser, Georg Schett, Steffen Gay and Oliver Distler

    Version of Record online : 28 DEC 2006, DOI: 10.1002/art.22314

  6. Intraoral hyperpigmentation due to imatinib mesylate. A review of the literature

    Oral Surgery

    Nilesh Pancholi and Pankaj Taneja

    Version of Record online : 15 OCT 2015, DOI: 10.1111/ors.12194

  7. Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate

    Liver International

    Volume 32, Issue 6, July 2012, Pages: 1008–1017, Youngchul Kim, Maria I. Fiel, Efsevia Albanis, Hsin I. Chou, Weijia Zhang, Gregory Khitrov and Scott L. Friedman

    Version of Record online : 16 APR 2012, DOI: 10.1111/j.1478-3231.2012.02806.x

  8. Imatinib mesylate in children and adolescents with cancer

    Pediatric Blood & Cancer

    Volume 55, Issue 1, 15 July 2010, Pages: 18–25, Ronald D. Barr

    Version of Record online : 1 APR 2010, DOI: 10.1002/pbc.22484

  9. You have free access to this content
    Imatinib mesylate alleviates diarrhea in a mouse model of intestinal allergy

    Neurogastroenterology & Motility

    Volume 24, Issue 7, July 2012, Pages: e325–e335, K. Vaali, J. Lappalainen, A. H. Lin, M. I. Mäyränpää, P. T Kovanen, A. Berstad and K. K. Eklund

    Version of Record online : 19 JUN 2012, DOI: 10.1111/j.1365-2982.2012.01941.x

  10. Imatinib Mesylate, the First Molecularly Targeted Gene Suppressor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 22, Issue 10, October 2002, Pages: 1249–1265, Vanita K. Pindolia and Barbara J. Zarowitz

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.22.15.1249.33482

  11. You have free access to this content
    Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate


    Volume 116, Issue 1, 1 January 2010, Pages: 184–192, Jonathan C. Trent, Shalin S. Patel, Jianhu Zhang, Dejka M. Araujo, Juan-Carlos Plana, Daniel J. Lenihan, Dominic Fan, Shreyaskumar R. Patel, Robert S. Benjamin and Aarif Y. Khakoo

    Version of Record online : 2 NOV 2009, DOI: 10.1002/cncr.24683

  12. You have free access to this content
    Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood–brain barrier

    Journal of Neurochemistry

    Volume 102, Issue 6, September 2007, Pages: 1749–1757, Sébastien Bihorel, Gian Camenisch, Michel Lemaire and Jean-Michel Scherrmann

    Version of Record online : 11 JUL 2007, DOI: 10.1111/j.1471-4159.2007.04808.x

  13. Sarcoma and Gastrointestinal Stromal Tumors

    Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach

    Markku Miettinen, Jerzy Lasota, Angela D. Levy, Heikki Joensuu, Ronald P. DeMatteo, Pages: 227–258, 2009

    Published Online : 14 JAN 2009, DOI: 10.1002/9781444300147.ch9

  14. You have free access to this content
    Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review

    European Journal of Haematology

    Volume 87, Issue 5, November 2011, Pages: 381–393, Shantashri Vaidya, Kanjaksha Ghosh and Babu Rao Vundinti

    Version of Record online : 2 OCT 2011, DOI: 10.1111/j.1600-0609.2011.01689.x

  15. You have full text access to this OnlineOpen article
    Suboptimal responses in chronic myeloid leukemia


    Volume 118, Issue 5, 1 March 2012, Pages: 1181–1191, Elias Jabbour, Giuseppe Saglio, Timothy P. Hughes and Hagop Kantarjian

    Version of Record online : 28 OCT 2011, DOI: 10.1002/cncr.26391

  16. Gastrointestinal Stromal Tumors

    Textbook of Uncommon Cancer

    Margaret von Mehren, Douglas B. Flieder, Chandrajit P. Raut, Pages: 465–483, 2012

    Published Online : 20 SEP 2012, DOI: 10.1002/9781118464557.ch33

  17. Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 9P2, September 2010, Pages: 77S–101S, Kamakshi V. Rao, Andrea Iannucci and Elias Jabbour

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.pt2.77S

  18. Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia

    Leukemias: Principles and Practice of Therapy

    Devendra K. Hiwase, Timothy P. Hughes, Pages: 281–295, 2011

    Published Online : 4 JAN 2011, DOI: 10.1002/9781444327359.ch23

  19. You have free access to this content
    Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 1, March 2012, Pages: 43–52, John R. ZALCBERG and Jayesh DESAI

    Version of Record online : 20 FEB 2012, DOI: 10.1111/j.1743-7563.2011.01491.x

  20. You have free access to this content
    Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia

    European Journal of Clinical Investigation

    Volume 42, Issue 9, September 2012, Pages: 1016–1026, Francis Giles, François-Xavier Mahon, Bjorn Gjertsen, Ronan Swords, Boris Labar, Anna Turkina and Gianantonio Rosti

    Version of Record online : 1 MAY 2012, DOI: 10.1111/j.1365-2362.2012.02675.x